Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasms × disitamab vedotin × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Stomach Neoplasms 10 Breast Neoplasms 10 Urinary Bladder Neoplasms 4 Carcinoma, Transitional Cell 4 Colorectal Neoplasms 3 Uterine Cervical Neoplasms 2 Ovarian Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 2 HER2-positive Gastric Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Solid Tumor 1 Pancreatic Neoplasms 1 Ovarian Cancer Recurrent 1 Neoplasms 1 Muscle Invasive Bladder Carcinoma 1 Muscle Invasive Bladder Cancer (MIBC) 1 Muscle Invasive Bladder Cancer 1 Metastatic HER2 Positive Gastroesophageal Junction Cancer 1 Lung Neoplasms 1 High-risk Non-muscle Invasive Bladder Cancer 1 Head and Neck Neoplasms 1 HER2-positive Metastatic Breast Cancer 1 HER2-low Breast Cancer 1 Endometrial Neoplasms 1 Castration-resistant Prostate Cancer 1 Biliary Tract Neoplasms 1 Advanced Breast Cancer 1

Interventions

pembrolizumab 155 Gemcitabine 146 Paclitaxel 134 Carboplatin 120 Bevacizumab 116 Docetaxel 100 Cyclophosphamide 100 Cisplatin 99 Exercise 82 Nivolumab 81 Capecitabine 80 Fluorouracil 78 Dexamethasone 74 Irinotecan 68 Oxaliplatin 62 Pemetrexed 60 Radiotherapy 59 Leucovorin 57 Standard of Care 56 Cetuximab 50 Blood Specimen Collection 48 Sorafenib 47 Drug Therapy 47 Erlotinib Hydrochloride 46 Doxorubicin 44 atezolizumab 41 130-nm albumin-bound paclitaxel 39 trametinib 37 Ipilimumab 36 Albumin-Bound Paclitaxel 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07142200 2025-08-26

DECIDING

RenJi Hospital

Phase 2 Not yet recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡